Ritonavir

From Wikipedia, the free encyclopedia



Ritonavir
Systematic (IUPAC) name
1,3-thiazol-5-ylmethyl [3-hydroxy-5- [3-methyl-2-[methyl- [(2-propan-2-yl-1,3-thiazol- 4-yl)methyl] carbamoyl] amino-butanoyl] amino-1,6-diphenyl-hexan-2-yl] aminoformate
Identifiers
CAS number	155213-67-5
ATC code	J05 AE03
PubChem	392622
DrugBank	APRD00312
Chemical data
Formula	C₃₇H₄₈N₆O₅S₂
Mol. weight	720.946 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	98-99%
Metabolism	?
Half life	3-5 hours
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Ritonavir, with trade name Norvir® (Abbott Laboratories), is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS.

Ritonavir is frequently prescribed with HAART, not for its antiviral action, but as it inhibits the same host enzyme that metabolizes other protease inhibitors. This inhibition leads to higher plasma concentrations of these latter drugs, allowing the clinician to lower their dose and frequency and improving their clinical efficacy.

1 History
2 Method of action
3 References
4 External links

[edit] History

Ritonavir is manufactured as Norvir® by Abbott Laboratories. Research that led to the drug's development was financed in part by a $3,500,000 federal grant through the National Institutes of Health (NIH). The Food and Drug Administration (FDA) approved ritonavir on March 1, 1996, making it the seventh approved antiretroviral drug in the United States. In 2003, Abbott raised the price of a Norvir course from USD $1.71 per day to $8.57 per day, leading to claims of price gouging by patients' groups and some members of Congress. Consumer group Essential Inventions petitioned the NIH to override the Norvir patent, but the NIH announced on August 4, 2004 that it would not invoke its legal right to allow generic production of Norvir, citing potential adverse effects on the pharmaceutical market.^[1]

[edit] Method of action

Ritanovir is exceptional as the only antiretroviral drug that inhibits a liver enzyme that normally metabolizes away protease inhibitors, Cytochrome P450-3A4 (CYP3A4). The drug's molecular structure inhibits CYP3A4, so a low dose can be used to enhance any other protease inhibitors. This effect does come with a price: it also affects the strength of numerous other medications, making it difficult to know how to administer them concurrently. In addition it can cause a large number of side-effects on its own. It is now rarely used for its own antiviral activity but remains widely used as a booster to other protease inhibitors.

[edit] References

↑ Ceci Connolly (2004-08-05). NIH Declines to Enter AIDS Drug Price Battle. Washington Post. Retrieved on 2006-01-16.

[edit] External links

Norvir (manufacturer's website)
Ritonavir (patient information)

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Antivirals (primarily J05A, also S01AD and D06BB) edit

Anti-herpesvirus agents		Aciclovir, Cidofovir, Docosanol, Famciclovir, Fomivirsen, Foscarnet, Ganciclovir, Idoxuridine, Penciclovir, Trifluridine, Tromantadine, Valaciclovir, Valganciclovir, Vidarabine
Anti-influenza agents		Amantadine, Oseltamivir, Peramivir, Rimantadine, Zanamivir

Antiretroviral drugs	NRTIs	Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Zalcitabine, Zidovudine
	NtRTIs	Tenofovir
	NNRTIs	Efavirenz, Delavirdine, Nevirapine
	PIs	Amprenavir, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir
	Fusion inhibitors	Enfuvirtide

Other antiviral agents		Adefovir, Fomivirsen, Imiquimod, Inosine,Interferon, Podophyllotoxin, Ribavirin, Viramidine